

Amendment No. 39

## MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		In accordance with letter dated June 3, 1987	
1. Wyoming Medical Center		3. License number 49-00152-02 is amended in its entirety to read as follows:	
2. 1233 East Second Street Casper, Wyoming 82601		4. Expiration date March 31, 1989	
		5. Docket or Reference No. 030-03495	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed	
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. As needed	
E. Any byproduct material identified in 10 CFR 35.500	E. Sealed sources for diagnostic devices identified in 10 CFR 35.500	E. millicuries per source	
F. Any byproduct material identified in 10 CFR 31.11	F. Prepackaged Kits	F. As needed	
9. Authorized Use:			
A. Medical use described in 10 CFR 35.100.			
B. Medical use described in 10 CFR 35.200.			
C. Medical use described in 10 CFR 35.300.			
D. Medical use described in 10 CFR 35.400. and, for Cesium-137, calibration of licensee's survey meters and personnel dosimeters.			
E. Medical use described in 10 CFR 35.500.			
F. <u>In vitro</u> studies.			

8801250112 870724  
REG4 LIC30  
49-00152-02 PDR

MATERIALS LICENSE  
SUPPLEMENTARY SHEETLicense number  
49-00152-02Docket or Reference number  
030-03495

Amendment No. 39

## CONDITIONS

10. Location of use: 1233 East Second Street, Casper, Wyoming.
11. Radiation Safety Officer: Warren S. Strayer, Jr.
12. Authorized Users:
  - A. Roger P. Mattson, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, 35.400, and 35.500; and for in vitro studies.
  - B. Carol F. Fellows, M.D., for material identified in 10 CFR 35.400 and 35.500.
  - C. Gregory Brondos, M.D., for in vitro studies.
  - D. Michael E. Walker, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, and 35.500; and for in vitro studies.
  - E. Marlene Moseburg, M.D., for material identified in 10 CFR 35.100, 35.200, and 35.500; and for in vitro studies.
  - F. James E. Killeen, M.D., for material identified in 10 CFR 35.100, 35.200, and 35.500; and for in vitro studies.
  - G. Steve E. Liston, M.D., for material identified in 10 CFR 35.100, 35.200, and 35.500; Iodine-131 for treatment of hyperthyroidism and cardiac dysfunction; Phosphorus-32 as soluble phosphate for treatment of polycythemia vera, leukemia, and bone metastases; and for in vitro studies.
  - H. Edward E. Tennant, M.D., for material identified in 10 CFR 35.400 and 35.500.
  - I. Stephen R. Horn, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, and 35.500; and for in vitro studies.
13. This license is based on the licensee's statements and representations dated September 2, 1983, January 24, 1984, February 6, 1984, March 6, 1984, August 27, 1985, and August 1, 1986.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Original signed by  
JACK E. WHITTEN

Date

Jul 24 1987

By

Nuclear Materials Licensing Section  
Region IV  
Arlington, Texas 76011

11 m44




UNITED STATES  
NUCLEAR REGULATORY COMMISSION

REGION IV  
611 RYAN PLAZA DRIVE, SUITE 1000  
ARLINGTON, TEXAS 76011

3/89

BETWEEN: William O. Miller, Chief  
License Fee Management Branch  
Office of Administration

R. J. Everett, Chief  
Material Radiation Protection Section, TPB,  
DV&TP, RIV



LICENSEE FEE TRANSMITTAL

A. REGION IV

1. APPLICATION ATTACHED

Applicant/Licensee:

Application Dated:

Control No.:

License No.:

Agony Medical Center

June 3, 1987

461529

49-00152-02(030-03495)

2. FEE ATTACHED

Amount:

Check No.:

3. COMMENTS

Signed

Date

Joe A. Marshall  
6/8/87

**FEE EXEMPT**

B. LICENSEE FEE MANAGEMENT BRANCH

1. Fee Category and Amount:

2. Correct Fee Paid. Application may be processed for:

Amendment ✓

Renewal                     

License                     

Signed

Date

M. Marshall  
6/8/87

Ex R 170.114(4) Col. 13